Efficacy and Safety of Acoramidis in Transthyretin Amyloid Cardiomyopathy

In patients with transthyretin amyloid cardiomyopathy, the TTR stabilizer acoramidis resulted in a better primary hierarchical outcome (including mortality, morbidity, and function) than placebo.

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The New England journal of medicine 2024-01, Vol.390 (2), p.132-142
Hauptverfasser:	Gillmore, Julian D., Judge, Daniel P., Cappelli, Francesco, Fontana, Marianna, Garcia-Pavia, Pablo, Gibbs, Simon, Grogan, Martha, Hanna, Mazen, Hoffman, James, Masri, Ahmad, Maurer, Mathew S., Nativi-Nicolau, Jose, Obici, Laura, Poulsen, Steen Hvitfeldt, Rockhold, Frank, Shah, Keyur B., Soman, Prem, Garg, Jyotsna, Chiswell, Karen, Xu, Haolin, Cao, Xiaofan, Lystig, Ted, Sinha, Uma, Fox, Jonathan C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adverse events Amyloidosis Amyloidosis - drug therapy Amyloidosis - pathology Brain natriuretic peptide Cardiology Cardiology General Cardiomyopathies - drug therapy Cardiomyopathies - pathology Cardiomyopathy Cardiovascular Agents - adverse effects Cardiovascular Agents - pharmacology Cardiovascular Agents - therapeutic use Death Design Dosage Double-Blind Method Functional Status Glomerular filtration rate Heart Heart Failure Hospitalization Humans Morbidity Myocarditis Natriuretic Peptide, Brain - analysis Patients Pericarditis Placebos Prealbumin - drug effects Prealbumin - therapeutic use Quality of life Statistical analysis Transplants & implants Transthyretin Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	In patients with transthyretin amyloid cardiomyopathy, the TTR stabilizer acoramidis resulted in a better primary hierarchical outcome (including mortality, morbidity, and function) than placebo.
ISSN:	0028-4793 1533-4406
DOI:	10.1056/NEJMoa2305434